JPH09227398A - Antiobese agent - Google Patents
Antiobese agentInfo
- Publication number
- JPH09227398A JPH09227398A JP8055402A JP5540296A JPH09227398A JP H09227398 A JPH09227398 A JP H09227398A JP 8055402 A JP8055402 A JP 8055402A JP 5540296 A JP5540296 A JP 5540296A JP H09227398 A JPH09227398 A JP H09227398A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- plant
- leaf
- leaves
- amylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は抗肥満剤、α−アミ
ラーゼ阻害剤、リパーゼ阻害剤及び飲食物に関する。詳
しくは食品中でエネルギー源となる糖質及び脂質の消化
吸収を抑制又は阻害することにより肥満の治療・予防を
行うための抗肥満剤、α−アミラーゼ阻害剤、リパーゼ
阻害剤及び飲食物に関する。TECHNICAL FIELD The present invention relates to an antiobesity agent, an α-amylase inhibitor, a lipase inhibitor and foods and drinks. More specifically, the present invention relates to an antiobesity agent, an α-amylase inhibitor, a lipase inhibitor, and a food or drink for treating or preventing obesity by suppressing or inhibiting digestion and absorption of sugars and lipids that are energy sources in foods.
【０００２】[0002]
【従来の技術】及び2. Description of the Related Art
【発明が解決しようとする課題】肥満は単なる美容上の
リスクばかりでなく、成人病など多くの疾病の要因とな
っている。その治療及び予防法としては、食事療法、運
動療法、薬物療法などが提案又は実施されている。しか
し、いずれの療法も栄養不良障害、運動機能障害、副作
用、空腹感あるいはストレスといった肉体的及び精神的
苦痛を患者に強いるものであり、効果を維持しがたいば
かりでなく、かえって健康を損なっている場合が多い。[0007] Obesity is not only a cosmetic risk, but also causes many diseases such as adult diseases. Diet therapy, exercise therapy, pharmacotherapy and the like have been proposed or implemented as the treatment and prevention methods. However, both of these therapies impose physical and mental distress on the patient such as malnutrition disorder, motor dysfunction, side effects, hunger and stress, and it is not only difficult to maintain the effect, but also the health is impaired. In many cases
【０００３】肥満の治療及び予防法としては、肉体的及
び精神的苦痛を強いることなく通常の食事形態をとりな
がら、余剰のエネルギーだけを最小限度の行為で除去
し、なおかつエネルギー源以外の栄養成分はできるだけ
除去しない方法が望まれる。食品中のエネルギー源はデ
ンプン等の糖質や、脂肪、脂肪酸、グリセリド、グリセ
ロール、コレステロール等の脂質が大部分であり、した
がってこれらの消化吸収を抑制又は阻害すれば肥満の治
療・予防ができるものと期待される。例としては、脂質
の消化吸収抑制機能を有する食品を利用する方法（特開
平３−２２８６６４号公報）、茶ポリフェノールによる
α−アミラーゼの活性を阻害する方法（特開平３−１３
３９２８号公報）、ドッカツ、リョウキョウ、ビンロウ
シ、ヨウバイヒ、サンペンズ、ケツメイシの抽出物によ
るリパーゼの活性を阻害する方法（特開平５−２５５１
００号公報）などが挙げられる。[0003] As a method for treating and preventing obesity, a surplus energy is removed by a minimum action while taking a normal diet without physical and mental distress, and a nutritional component other than an energy source is used. A method that does not remove as much as possible is desirable. Most energy sources in foods are sugars such as starch and lipids such as fats, fatty acids, glycerides, glycerol and cholesterol. Therefore, if these digestion and absorption are suppressed or inhibited, obesity can be treated or prevented. Is expected. As an example, a method of using a food having a function of suppressing digestion and absorption of lipids (JP-A-3-228664) and a method of inhibiting the activity of α-amylase by tea polyphenol (JP-A-3-13)
No. 3928), a method for inhibiting the activity of lipase by the extracts of Dokkatsu, Ryokyo, Areca, Spodoptera litura, Sampens, and Tsutsumeishi (Japanese Patent Laid-Open No. 5-2551).
No. 00).
【０００４】α−アミラーゼは糖質の消化酵素であり、
ヒトにおいては唾液腺、耳下腺、膵臓から分泌される。
α−アミラーゼ阻害剤は、肥満の治療・予防のほか、糖
尿病の治療・予防にも効果があると考えられている。[0004] α-amylase is a carbohydrate digestive enzyme,
In humans, it is secreted from salivary glands, parotid glands, and pancreas.
α-Amylase inhibitors are thought to be effective in treating and preventing obesity as well as in treating and preventing diabetes.
【０００５】リパーゼは脂質の消化酵素であり、ヒトに
おいては膵臓から分泌されるほか、Candida cylindracc
aeに代表される皮膚表層に常在する微生物によって産生
される。リパーゼ阻害剤は、肥満の治療・予防のほか、
高脂血症、動脈硬化症、ニキビ、皮膚炎の治療・予防に
も効果があると考えられている。[0005] Lipase is a digestive enzyme for lipids, which is secreted from the pancreas in humans, and Candida cylindracc.
It is produced by microorganisms resident on the skin surface represented by ae. Lipase inhibitors are used to treat and prevent obesity,
It is also thought to be effective in treating and preventing hyperlipidemia, arteriosclerosis, acne, and dermatitis.
【０００６】したがって、α−アミラーゼ阻害作用、リ
パーゼ阻害作用を併せもち、他の栄養成分に影響を与え
ず、かつ副作用の少ない予防・治療剤が望まれている。Therefore, a prophylactic / therapeutic agent which has both an α-amylase inhibitory action and a lipase inhibitory action, does not affect other nutritional components, and has few side effects is desired.
【０００７】[0007]
【課題を解決するための手段】本発明者らは前記事情に
鑑み研究を行った結果、ブドウ種子、カキ葉、プーアル
茶、オトギリソウ、リンゴ、タラ、ウラジロガシ、バナ
バ葉、アカメガシワ、サンシュユ、訶子、トチュウ葉の
抽出物が糖質及び脂質の消化吸収を阻害し、かつα−ア
ミラーゼ及びリパーゼを阻害することを見出し、本発明
を完成した。[Means for Solving the Problems] As a result of studies conducted by the present inventors in view of the above circumstances, grape seeds, oyster leaves, Pu'er tea, Hypericum perforatum, apples, cod, veiled oak, banaba leaves, Akamegashiwa, Sanshuyu, syrup The inventors have found that Eucommia ulmoides leaf extract inhibits digestion and absorption of sugars and lipids and inhibits α-amylase and lipase, and completed the present invention.
【０００８】即ち、本発明はブドウ種子、カキ葉、プー
アル茶、オトギリソウ、リンゴ、タラ、ウラジロガシ、
バナバ葉、アカメガシワ、サンシュユ、訶子、トチュウ
葉から選ばれる少なくとも１種の植物の抽出物を有効成
分とする抗肥満剤に関する。That is, the present invention relates to grape seeds, oyster leaves, puer tea, Hypericum perforatum, apple, cod, veiled oak,
The present invention relates to an antiobesity agent containing as an active ingredient an extract of at least one plant selected from banaba leaves, Akamegashiwa, Sanshuyu, licorice, and Eucommia leaves.
【０００９】また、本発明はブドウ種子、カキ葉、プー
アル茶、オトギリソウ、リンゴ、タラ、ウラジロガシ、
バナバ葉、アカメガシワ、サンシュユ、訶子、トチュウ
葉から選ばれる少なくとも１種の植物の抽出物を有効成
分とするα−アミラーゼ阻害剤に関する。The present invention also relates to grape seeds, oyster leaves, puerh tea, Hypericum perforatum, apple, cod, veiled oak,
The present invention relates to an α-amylase inhibitor containing, as an active ingredient, an extract of at least one plant selected from banaba leaves, Akamega wrinkles, Sanshuyu, licorice, and eucommia leaves.
【００１０】さらに、本発明はブドウ種子、カキ葉、プ
ーアル茶、オトギリソウ、リンゴ、タラ、ウラジロガ
シ、バナバ葉、アカメガシワ、サンシュユ、訶子、トチ
ュウ葉から選ばれる少なくとも１種の植物の抽出物を有
効成分とするリパーゼ阻害剤に関する。Further, the present invention is effective with an extract of at least one plant selected from grape seeds, oyster leaves, puer tea, Hypericum perforatum, apple, cod, veiled oak, banaba leaf, Akamegashiwa, Sanshuyu, licorice and eucommia leaves. The present invention relates to a lipase inhibitor as a component.
【００１１】さらにまた、本発明はブドウ種子、オトギ
リソウ、タラ、ウラジロガシ、アカメガシワ、サンシュ
ユ、訶子から選ばれる少なくとも１種の植物の抽出物を
食品又は飲料に加えてなる飲食物に関する。Furthermore, the present invention relates to a food or drink obtained by adding an extract of at least one plant selected from grape seeds, Hypericum perforatum, cod, veiled oak, Red Megalochis, Sanshuyu, and licorice to a food or beverage.
【００１２】本発明に用いられるブドウ種子は、ブドウ
科ブドウの種子であり、フランスでは動脈硬化症の治療
薬として使用されている。The grape seed used in the present invention is a seed of the grape family Vineae, and is used as a therapeutic drug for arteriosclerosis in France.
【００１３】本発明に用いられるカキ葉は、カキ科カキ
の葉であり、民間では健康茶として用いられている。The oyster leaf used in the present invention is an oyster leaf of the oyster family and is used as a health tea in the private sector.
【００１４】本発明に用いられるプーアル茶は、緑茶を
黒麹菌を用いて発酵させたものであり、中国では古くか
ら飲料として利用されている。The puer tea used in the present invention is obtained by fermenting green tea with Aspergillus niger and has been used as a beverage in China since ancient times.
【００１５】本発明に用いられるオトギリソウは、オト
ギリソウ科オトギリソウ全草であり、その煎剤は止血、
収れん、含そう薬として用いられている。The Hypericum perforatum used in the present invention is a whole plant of Hypericum perforataceae, the decoction of which is hemostatic.
It is used as an astringent and a mouthwash.
【００１６】本発明に用いられるリンゴ、特にその未熟
果の抽出物は、酸化防止や虫歯予防目的の食品添加物と
して利用されている。The apple used in the present invention, especially the extract of the immature fruit thereof, is utilized as a food additive for the purpose of preventing oxidation and preventing dental caries.
【００１７】本発明に用いられるタラは、ウコギ科タラ
ノキの樹皮であり、民間薬として糖尿病に用いられてい
る。The cod used in the present invention is the bark of the Araliaceae cod, which is used as a folk medicine for diabetes.
【００１８】本発明に用いられるウラジロガシは、ブナ
科ウラジロガシの樹皮であり、胆石、尿路結石の民間薬
として知られている。The white-tailed oak used in the present invention is the bark of the white-eye veiled beetle, and is known as a folk medicine for gallstones and urinary tract stones.
【００１９】本発明に用いられるバナバ葉は、ミソハギ
科オオバナサルスベリの葉であり、フィリピンでは糖尿
病などの民間薬として、また健康茶として古くから用い
られている。The banaba leaf used in the present invention is a leaf of the Myrtleaceae, Giant Clover, which has long been used as a folk medicine for diabetes and health tea in the Philippines.
【００２０】本発明に用いられるアカメガシワは、トウ
ダイグサ科アカメガシワの樹皮であり、潰瘍や胆石症に
用いられている。The red wrinkle used in the present invention is the bark of the red spruce of the Euphorbiaceae family, and is used for ulcers and cholelithiasis.
【００２１】本発明に用いられるサンシュユは、ミズキ
科サンシュユの果実であり、滋養、強壮、収れん薬とし
て使用される。Sanshuyu used in the present invention is a fruit of Sanshuyu, a family of the dogwood family, and is used as a nourishing, tonic and astringent drug.
【００２２】本発明に用いられる訶子（カシ）は、シク
ンシ科ミロバランの果実であり、インドのアユルベーダ
医学の要薬として用いられるほか、皮なめしの材料とし
ても用いられている。The moss (oak) used in the present invention is a fruit of Myrobalan, which is a member of the family Asteraceae, and is used not only as an essential drug in Ayurvedic medicine in India but also as a material for skin tanning.
【００２３】本発明に用いられるトチュウ葉は、トチュ
ウ科トチュウの葉であり、民間では健康茶として用いら
れている。The eucommia leaf used in the present invention is an eucommia leaf of the Eucommia family and is used as health tea in the private sector.
【００２４】本発明において抽出物とは、植物を極性又
は非極性溶媒で抽出して得られる抽出液、その希釈液、
濃縮液、エキス又は乾燥物を意味する。溶媒としては、
例えばメタノール、エタノール、１−プロパノール、２
−プロパノール、１−ブタノール、２−ブタノール等の
アルコール類、エーテル、テトラヒドロフラン等のエー
テル類、酢酸エチル等のエステル類、アセトン等のケト
ン類、アセトニトリル等のニトリル類、ベンゼン、トル
エン等の芳香族炭化水素類、塩化メチレン、クロロホル
ム等のハロゲン化脂肪族炭化水素類、水等を適宜選択し
て使用することができるが、抽出後の使用における安全
性及び便宜の観点からはメタノール、エタノール、１−
プロパノール、２−プロパノール、１−ブタノール、２
−ブタノール等のアルコール類、水が好ましい。In the present invention, the extract means an extract obtained by extracting a plant with a polar or non-polar solvent, a diluted solution thereof,
It means a concentrated liquid, an extract or a dried product. As the solvent,
For example, methanol, ethanol, 1-propanol, 2
-Alcohols such as propanol, 1-butanol and 2-butanol, ethers such as ether and tetrahydrofuran, esters such as ethyl acetate, ketones such as acetone, nitriles such as acetonitrile, aromatic carbonization such as benzene and toluene. Hydrogen, methylene chloride, halogenated aliphatic hydrocarbons such as chloroform, water and the like can be appropriately selected and used, but from the viewpoint of safety and convenience in use after extraction, methanol, ethanol, 1-
Propanol, 2-propanol, 1-butanol, 2
-Alcohols such as butanol and water are preferred.
【００２５】[0025]
【発明の実施の形態】本発明の抽出物は、例えば、植物
又はその乾燥物を粉砕、破砕、裁断し、これに５倍〜２
００倍量の極性又は非極性溶媒を加え、０℃〜還流温度
の範囲で５分〜４８時間撹拌、静置及び／又はホモジナ
イズして抽出を行う。抽出後、濾過、遠心分離等の操作
を行い不溶物を除き、必要に応じて希釈、濾過、濃縮操
作を行うことにより目的とする抽出物を得ることができ
る。必要ならば、不溶物を前記と同様の操作により抽出
し、その抽出液を合わせて使用することもできる。BEST MODE FOR CARRYING OUT THE INVENTION The extract of the present invention is obtained by, for example, crushing, crushing, or cutting a plant or a dried product thereof, and adding 5 to 2
A 00-fold amount of polar or non-polar solvent is added, and the mixture is stirred at 0 ° C to reflux temperature for 5 minutes to 48 hours, allowed to stand and / or homogenized for extraction. After the extraction, operations such as filtration and centrifugation are performed to remove insolubles, and if necessary, dilution, filtration, and concentration operations are performed to obtain a target extract. If necessary, the insoluble matter can be extracted by the same operation as described above, and the extracts can be used together.
【００２６】本発明の抽出物は、そのままでも使用する
ことができるが、適当な溶媒で希釈又は濃縮することも
でき、単独あるいは適当な担体とともに噴霧乾燥、凍結
乾燥、減圧乾燥、流動乾燥等の公知の方法により粉末状
とするか、慣用の添加剤を用いることにより液剤、錠剤
若しくは顆粒剤等にして使用することができる。こうし
て製剤化された本発明の抽出物は、抗肥満剤、α−アミ
ラーゼ阻害剤、リパーゼ阻害剤等の薬剤として用いた
り、また種々の食品に添加することにより使用すること
ができる。The extract of the present invention can be used as it is, but it can also be diluted or concentrated with a suitable solvent, and can be spray-dried, freeze-dried, vacuum-dried, fluidized-dried or the like alone or together with a suitable carrier. It can be made into a powder by a known method, or can be used as a liquid, tablet, granule or the like by using a conventional additive. The extract of the present invention thus formulated can be used as a drug such as an anti-obesity agent, an α-amylase inhibitor, a lipase inhibitor or the like, or can be used by adding it to various foods.
【００２７】[0027]
【作用】本発明の抗肥満剤は、強い糖質及び脂質吸収阻
害作用を有し、肥満の治療・予防に有用である。また本
発明の抗肥満剤は、後述の実施例より、緑茶と比較して
強い糖質及び脂質吸収阻害作用を有する一方、タンパク
質吸収阻害作用が弱いため、体の構成成分となるタンパ
ク質の吸収を阻害することなく安全に肥満の治療・予防
が可能である。The antiobesity agent of the present invention has a strong carbohydrate and lipid absorption inhibitory effect and is useful for treating and preventing obesity. In addition, the antiobesity agent of the present invention has a stronger inhibitory effect on carbohydrate and lipid absorption than green tea, but has a weaker protein absorption inhibitory effect than green tea. It is possible to treat and prevent obesity safely without inhibition.
【００２８】また本発明のα−アミラーゼ阻害剤は、肥
満の治療・予防のほか、α−アミラーゼに起因する糖尿
病の治療・予防に有用である。The α-amylase inhibitor of the present invention is useful not only for treating and preventing obesity but also for treating and preventing diabetes caused by α-amylase.
【００２９】さらに本発明のリパーゼ阻害剤は、肥満の
治療・予防のほか、リパーゼに起因する高脂血症、動脈
硬化症、ニキビ、皮膚炎の治療・予防に有用である。Further, the lipase inhibitor of the present invention is useful for treating and preventing obesity as well as treating and preventing hyperlipidemia, arteriosclerosis, acne and dermatitis caused by lipase.
【００３０】[0030]
【実施例】以下に実施例を挙げて本発明をさらに詳細に
説明するが、本発明はこれらに限定されるものではな
い。以下に挙げるデンプン消化力試験、脂肪消化力試
験、タンパク質消化力試験はそれぞれ糖質、脂質、タン
パク質の消化吸収力の度合いを測定したものであり、特
にパンクレアチンのうち糖質を消化する酵素、脂質を消
化する酵素、タンパク質を消化する酵素のそれぞれの酵
素活性を阻害する度合いを測定したものである。また、
α−アミラーゼ阻害試験、リパーゼ阻害試験はそれぞれ
α−アミラーゼ、リパーゼの酵素活性の阻害度合いを測
定したものである。The present invention will be described in more detail with reference to the following examples, but the present invention is not limited thereto. The following starch digestion test, fat digestion test, and protein digestion test measure the degree of digestion and absorption of sugars, lipids, and proteins, respectively, and in particular, an enzyme that digests sugars in pancreatin, The degree of inhibition of the enzyme activity of each of the enzyme that digests lipid and the enzyme that digests protein was measured. Also,
The α-amylase inhibition test and the lipase inhibition test measure the degree of inhibition of the enzyme activities of α-amylase and lipase, respectively.
【００３１】＜試料溶液の調製＞ブドウ種子は室温下で
１０倍量のアセトンによる抽出を５回繰り返し、抽出液
を濾過した後減圧濃縮し、さらに室温下で５倍量の１−
ブタノールによる抽出を５回繰り返し、抽出液を減圧濃
縮後噴霧乾燥したものを抽出エキスとした。<Preparation of Sample Solution> Grape seeds were extracted with 10 volumes of acetone at room temperature 5 times repeatedly, and the extract was filtered and concentrated under reduced pressure.
Extraction with butanol was repeated 5 times, and the extract was concentrated under reduced pressure and spray-dried to obtain an extract.
【００３２】カキ葉、プーアル茶、オトギリソウ、タ
ラ、ウラジロガシ、バナバ葉、アカメガシワ、サンシュ
ユ、訶子、トチュウ葉はその乾燥物を粉砕し、粉砕物に
対して１００倍量の５０％エタノールを加え、１時間加
熱還流後抽出液を濾過し、濾液を減圧濃縮したものを抽
出エキスとした。Oyster leaves, puerh tea, Hypericum perforatum, cod, veiled oak, Banaba leaf, Akamegashiwa, Sanshuyu, licorice, eucommia leaves are crushed dry matter, and 100 times amount of 50% ethanol is added to the crushed matter, After heating under reflux for 1 hour, the extract was filtered, and the filtrate was concentrated under reduced pressure to obtain an extract.
【００３３】リンゴはその未熟果を、室温下１０倍量の
８０％エタノール中でホモジナイズ後抽出液を濾過し、
その濾液を減圧濃縮後吸着カラムにより精製し、減圧濃
縮したものを抽出エキスとした。For apples, their immature fruits were homogenized at room temperature in 10 volumes of 80% ethanol, and the extract was filtered.
The filtrate was concentrated under reduced pressure, purified by an adsorption column, and concentrated under reduced pressure to obtain an extract.
【００３４】比較検体として、市販の小麦抽出エキス
（小麦エキス−α：タマ生化学（株）製）及び緑茶抽出
エキス（ポリフェノン−６０：三井農林（株）製）を用
いた。Commercially available wheat extract (wheat extract-α: Tama Biochemical Co., Ltd.) and green tea extract (Polyphenon-60: Mitsui Norin Co., Ltd.) were used as comparative samples.
【００３５】これらの抽出エキスは任意の割合で精製水
を加え、試料溶液を調製した。Purified water was added to these extracts at an arbitrary ratio to prepare a sample solution.
【００３６】実施例１ ＜デンプン消化力試験＞試料溶液９mlと酵素溶液（４．
５倍パンクレアチン０．１mg/ml：天野製薬（株）製）
１mlを試験管に加えてよく混合し、３７℃で１０分間放
置した後、１％バレイショデンプン溶液（ｐＨ７．０）
１０mlを加え直ちに振り混ぜた。この液を３７℃で１０
分間放置後、この液１mlを０．１Ｎ塩酸１０mlに注入し
て反応を停止させた。この液１mlを着色液（０．０００
４Ｎヨウ素試液）１０mlに加え、振り混ぜた後波長６６
０nmにおける吸光度ＡTを測定した。別に、対照として
試料溶液の代わりに水を、またブランクとして試料溶液
と酵素溶液の代わりに水を、それぞれ加え以下同様に操
作して吸光度ＡS及びＡBを測定した。Example 1 <Starch digestion test> 9 ml of sample solution and enzyme solution (4.
5-fold pancreatin 0.1 mg / ml: manufactured by Amano Pharmaceutical Co., Ltd.)
1 ml was added to the test tube, mixed well, left at 37 ° C. for 10 minutes, and then 1% potato starch solution (pH 7.0)
10 ml was added and shaken immediately. This solution is added at 37 ° C for 10
After standing for 1 minute, 1 ml of this solution was poured into 10 ml of 0.1N hydrochloric acid to stop the reaction. 1 ml of this solution is colored (0.000
4N iodine test solution) 10ml, shake and mix at wavelength 66
The absorbance AT at 0 nm was measured. Separately, water was used instead of the sample solution as a control, and water was used as a blank instead of the sample solution and the enzyme solution, and the absorbances AS and AB were measured in the same manner.
【００３７】実施例２ ＜脂肪消化力試験＞試料溶液１ml、緩衝液（１２５mMＴ
ｒｉｓ−ＨＣｌ、ｐＨ７．４）２ml及び酵素溶液（４．
５倍パンクレアチン０．５mg/ml：天野製薬（株）製）
１mlを試験管に加えてよく混合し、３７℃で１０分間放
置した後、２％大豆油（０．５％アラビアガム水溶液に
エマルジョン化）１mlを加え直ちに振り混ぜた。この液
を３７℃で１０分間放置後、クロロホルム１０mlを加え
５分間攪拌して反応を停止させた。クロロホルム層を分
取し、同量の着色液（硝酸銅(II)三水和物３．２g、ト
リエタノールアミン６．７g、酢酸０．３gを精製水に溶
解し、全量を１００mlとしたもの）を加え５分間攪拌し
た。このクロロホルム層を分取し、同量の発色液（０．
１％ジエチルジチオカルバミン酸ナトリウムの１−ブタ
ノール溶液）を加え、攪拌後波長４４０nmにおける吸光
度ＡTを測定した。別に、対照として試料溶液の代わり
に水を、またブランクとして試料溶液と酵素溶液の代わ
りに水を、それぞれ加え以下同様に操作して吸光度ＡS
及びＡBを測定した。Example 2 <Fat digestion test> Sample solution 1 ml, buffer solution (125 mM
2 ml of ris-HCl, pH 7.4 and enzyme solution (4.
5-fold pancreatin 0.5 mg / ml: manufactured by Amano Pharmaceutical Co., Ltd.)
1 ml was added to a test tube, mixed well, allowed to stand at 37 ° C. for 10 minutes, then 1 ml of 2% soybean oil (emulsified in 0.5% aqueous solution of gum arabic) was added and immediately shaken. After leaving this solution at 37 ° C. for 10 minutes, 10 ml of chloroform was added and stirred for 5 minutes to stop the reaction. The chloroform layer was separated, and the same amount of a colored liquid (3.2 g of copper (II) nitrate trihydrate, 6.7 g of triethanolamine, and 0.3 g of acetic acid dissolved in purified water to make a total volume of 100 ml). ) Was added and stirred for 5 minutes. The chloroform layer was collected and the same amount of the coloring solution (0.
After adding 1% sodium diethyldithiocarbamate in 1-butanol) and stirring, the absorbance AT at a wavelength of 440 nm was measured. Separately, water was used instead of the sample solution as a control, and water was used as a blank, instead of the sample solution and the enzyme solution.
And AB were measured.
【００３８】実施例３ ＜タンパク質消化力試験＞試料溶液４ml及び酵素溶液
（４．５倍パンクレアチン０．５mg/ml：天野製薬
（株）製）１mlを試験管に加えてよく混合し、３７℃で
１０分間放置した後、０．６％ミルクカゼイン溶液（ｐ
Ｈ８．０）５mlを加え直ちに振り混ぜた。この液を３７
℃で１０分間放置後、０．１１Ｍトリクロル酢酸溶液５
mlを加え３７℃で１０分間攪拌して反応を停止させた
後、濾過した。濾液２mlに０．５５Ｍ炭酸ナトリウム試
液５mlと着色液（３倍希釈フォリン試液）１mlを加え、
直ちに振り混ぜ３７℃で３０分間放置後波長６６０nmに
おける吸光度ＡTを測定した。別に、対照として試料溶
液の代わりに水を加え同様に操作して吸光度ＡSを測定
し、またブランクとして試料溶液と酵素溶液の代わりに
水を、反応停止時に酵素溶液を加え以下同様に操作して
ＡBを測定した。Example 3 <Protein digestibility test> 4 ml of a sample solution and 1 ml of an enzyme solution (4.5 times pancreatin 0.5 mg / ml: Amano Pharmaceutical Co., Ltd.) were added to a test tube and mixed well, 37 After standing at ℃ for 10 minutes, 0.6% milk casein solution (p
H8.0) was added and shaken immediately. 37
After leaving at 10 ° C for 10 minutes, 0.11M trichloroacetic acid solution
The reaction was terminated by adding 10 ml and stirring at 37 ° C. for 10 minutes, followed by filtration. To 2 ml of the filtrate, 5 ml of a 0.55 M sodium carbonate test solution and 1 ml of a coloring solution (3-fold diluted folin solution) were added.
Immediately after shaking and standing at 37 ° C. for 30 minutes, the absorbance AT at a wavelength of 660 nm was measured. Separately, water was used instead of the sample solution as a control and the absorbance AS was measured in the same manner, and water was used instead of the sample solution and the enzyme solution as a blank, and the enzyme solution was added when the reaction was stopped. AB was measured.
【００３９】実施例４ ＜α−アミラーゼ阻害試験１＞実施例１において、酵素
溶液としてヒト唾液由来α−アミラーゼ４units/ml（シ
グマ製：１unitは２０℃、ｐＨ６．９においてデンプン
から１mg/３minのマルトースを遊離させる酵素量）を用
いた以外は実施例１と同様の操作により、吸光度ＡT、
ＡS及びＡBを測定した。Example 4 <α-Amylase Inhibition Test 1> In Example 1, human saliva-derived α-amylase 4 units / ml (manufactured by Sigma: 1 unit at 20 ° C., pH 6.9 was 1 mg / 3 min from starch) as an enzyme solution. The same procedure as in Example 1 except that the amount of enzyme that releases maltose) was used, and the absorbance AT,
AS and AB were measured.
【００４０】実施例５ ＜α−アミラーゼ阻害試験２＞実施例１において、酵素
溶液としてブタ膵液由来α−アミラーゼ４units/ml（シ
グマ製：１unitは２０℃、ｐＨ６．９においてデンプン
から１mg/３minのマルトースを遊離させる酵素量）を用
いた以外は実施例１と同様の操作により、吸光度ＡT、
ＡS及びＡBを測定した。Example 5 <α-Amylase Inhibition Test 2> In Example 1, 4 units / ml of porcine pancreatic juice-derived α-amylase as an enzyme solution (manufactured by Sigma: 1 unit was 20 mg at a temperature of 6.9 at 1 mg / 3 min from starch) The same procedure as in Example 1 except that the amount of enzyme that releases maltose) was used, and the absorbance AT,
AS and AB were measured.
【００４１】実施例６ ＜リパーゼ阻害試験１＞実施例２において、酵素溶液と
してブタ膵液由来リパーゼ２００units/ml（シグマ製：
１unitは３７℃、ｐＨ７．８において乳化オリーブ油か
ら１μmole/hrの脂肪酸を遊離させる酵素量）を用いた
以外は実施例２と同様の操作により、吸光度ＡT、ＡS及
びＡBを測定した。Example 6 <Lipase Inhibition Test 1> In Example 2, as an enzyme solution, 200 units / ml of porcine pancreatic juice-derived lipase (manufactured by Sigma:
Absorbances AT, AS and AB were measured in the same manner as in Example 2 except that 1 unit used an enzyme amount which releases 1 μmole / hr of fatty acid from emulsified olive oil at 37 ° C. and pH 7.8.
【００４２】実施例７ ＜リパーゼ阻害試験２＞実施例２において、酵素溶液と
してCandida cylindraccae由来リパーゼ０．０７units/
ml（ウォルシントン・バイオケミカル製：１unitは２５
℃、ｐＨ８．０において乳化オリーブ油から１μmole/m
inの脂肪酸を遊離させる酵素量）を用いた以外は実施例
２と同様の操作により、吸光度ＡT、ＡS及びＡBを測定
した。Example 7 <Lipase inhibition test 2> In Example 2, as an enzyme solution, Candida cylindraccae-derived lipase 0.07 units /
ml (manufactured by Walsington Biochemical: 1 unit is 25
1 μmole / m from emulsified olive oil at ℃, pH 8.0
The absorbances AT, AS and AB were measured in the same manner as in Example 2 except that the amount of the enzyme that liberated the fatty acid in was used.
【００４３】各実施例の測定結果より下式を用いて阻害
率を算出し、試料の濃度に対して対数プロットをとりＩ
Ｃ50（酵素活性を５０％阻害するのに必要な抽出エキス
の重量）を求めた。The inhibition rate was calculated from the measurement result of each Example using the following formula, and a logarithmic plot was taken with respect to the concentration of the sample to obtain I
C50 (weight of the extract required to inhibit the enzyme activity by 50%) was determined.
【００４４】[0044]
【数１】 [Equation 1]
【００４５】試験結果を以下に示す。The test results are shown below.
【００４６】[0046]
【表１】 [Table 1]
【００４７】[0047]
【表２】 [Table 2]
【００４８】[0048]
【発明の効果】実施例から明らかなように、本発明の植
物抽出物は糖質及び脂質の消化吸収を強力に阻害し、タ
ンパク質の消化吸収を阻害しないため、エネルギー源以
外の栄養成分に影響を与えない、肥満の治療・予防剤と
して有用である。また、α−アミラーゼ阻害作用及びリ
パーゼ阻害作用も有するので、肥満症ばかりでなく糖尿
病、高脂血症、動脈硬化症、ニキビ、皮膚炎等の治療・
予防にも有用である。As is apparent from the examples, the plant extract of the present invention strongly inhibits digestion and absorption of sugars and lipids and does not inhibit digestion and absorption of proteins, and thus affects nutrient components other than energy sources. It is useful as a therapeutic / preventive agent for obesity. Further, since it also has an α-amylase inhibitory action and a lipase inhibitory action, it is possible to treat not only obesity but also diabetes, hyperlipidemia, arteriosclerosis, acne, dermatitis, etc.
It is also useful for prevention.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 ＦＩ 技術表示箇所 Ｃ１２Ｎ 9/99 Ｃ１２Ｎ 9/99 ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI Technical indication C12N 9/99 C12N 9/99
Claims (6)
ギリソウ、リンゴ、タラ、ウラジロガシ、バナバ葉、ア
カメガシワ、サンシュユ、訶子、トチュウ葉から選ばれ
る少なくとも１種の植物の抽出物を有効成分とする抗肥
満剤。1. An extract containing at least one plant selected from grape seeds, oyster leaves, puer tea, Hypericum perforatum, apple, cod, vagado oak, banaba leaf, Akamegashiwa, Sanshuyu, licorice and eucommia leaves as an active ingredient. Antiobesity agent.
基づく請求項１記載の抗肥満剤。2. The anti-obesity agent according to claim 1, wherein the anti-obesity effect is based on an α-amylase inhibitory effect.
請求項１記載の抗肥満剤。3. The anti-obesity agent according to claim 1, wherein the anti-obesity effect is based on a lipase inhibitory effect.
ギリソウ、リンゴ、タラ、ウラジロガシ、バナバ葉、ア
カメガシワ、サンシュユ、訶子、トチュウ葉から選ばれ
る少なくとも１種の植物の抽出物を有効成分とするα−
アミラーゼ阻害剤。4. An effective ingredient is an extract of at least one plant selected from grape seeds, oyster leaves, puer tea, Hypericum perforatum, apple, cod, veiled oak, banaba leaf, Akamegashiwa, Sanshuyu, licorice and eucommia leaves. α-
Amylase inhibitor.
ギリソウ、リンゴ、タラ、ウラジロガシ、バナバ葉、ア
カメガシワ、サンシュユ、訶子、トチュウ葉から選ばれ
る少なくとも１種の植物の抽出物を有効成分とするリパ
ーゼ阻害剤。5. An extract containing at least one plant selected from grape seeds, oyster leaves, puer tea, Hypericum perforatum, apple, cod, veiled oak, banaba leaf, Akamegashiwa, Sanshuyu, licorice and eucommia leaves as an active ingredient. Lipase inhibitor.
ジロガシ、アカメガシワ、サンシュユ、訶子から選ばれ
る少なくとも１種の植物の抽出物を食品又は飲料に加え
てなる飲食物。6. A food or drink comprising an extract of at least one plant selected from grape seeds, Hypericum perforatum, cod, Vladimir oak, Akamegashiwa, Sanshuyu, and licorice, added to a food or beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8055402A JPH09227398A (en) | 1996-02-20 | 1996-02-20 | Antiobese agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8055402A JPH09227398A (en) | 1996-02-20 | 1996-02-20 | Antiobese agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09227398A true JPH09227398A (en) | 1997-09-02 |
Family
ID=12997553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP8055402A Pending JPH09227398A (en) | 1996-02-20 | 1996-02-20 | Antiobese agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH09227398A (en) |
Cited By (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034630A1 (en) * | 1997-02-05 | 1998-08-13 | F.Hoffmann-La Roche Ag | Use of gastrointestinal lipase inhibitors |
| JPH10304848A (en) * | 1997-05-07 | 1998-11-17 | Hitachi Zosen Corp | Food having anti-hyperlipemic function |
| JPH11276148A (en) * | 1998-03-30 | 1999-10-12 | Kazuichi Watabe | Production of wine of hypericum erectum |
| JPH11332561A (en) * | 1998-05-22 | 1999-12-07 | Matsuura Yakugyo Kk | Angiotensin converting enzyme inhibitor |
| JP2000044484A (en) * | 1998-07-31 | 2000-02-15 | Higashimaru Shoyu Co Ltd | Amylase inhibition-active substance and its use |
| JP2000053568A (en) * | 1998-08-06 | 2000-02-22 | Taiyo Kagaku Co Ltd | Anti-obesity composition |
| JP2000191487A (en) * | 1998-12-29 | 2000-07-11 | Sunstar Inc | Oral cavity agent composition and food and drink composition for inhibiting matrix metalloprotease |
| JP2001048802A (en) * | 1999-08-06 | 2001-02-20 | Kenko Tsusho Kk | Health auxiliary food effective for diabetes, method of using the same and food combination preparation effective for diabetes |
| WO2000054760A3 (en) * | 1999-03-15 | 2001-03-08 | Shaman Pharmaceuticals Inc | Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia |
| JP2001103928A (en) * | 1999-10-08 | 2001-04-17 | Fancl Corp | Food composition |
| JP2001206893A (en) * | 1999-11-17 | 2001-07-31 | Sanpo Kk | NEW alpha-AMYLASE INHIBITORY ACTIVE SUBSTANCE, METHOD FOR PRODUCING THE SAME AND ITS USE |
| JP2001333733A (en) * | 2000-05-29 | 2001-12-04 | Okinawa Shokuryo Kk | alpha-AMYLASE INHIBITOR |
| EP1166790A1 (en) * | 2000-06-28 | 2002-01-02 | Ito En, Ltd. | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage |
| JP2002275077A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipase inhibitor |
| JP2003113106A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Expression promoter of uncoupling protein and composition containing the same |
| JP2003128563A (en) * | 2001-10-25 | 2003-05-08 | Ichimaru Pharcos Co Ltd | Cosmetic composition, drink or food |
| JP2003252766A (en) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | Antiobesity and/or antidiabetic agent containing cyanidin 3-glucoside as active component |
| JP2003342185A (en) * | 2002-05-25 | 2003-12-03 | Bhn Kk | Inhibitor of lipase activity |
| JP2004000164A (en) * | 2002-03-29 | 2004-01-08 | Morinaga Milk Ind Co Ltd | alpha-GLUCOSIDASE INHIBITOR AND COMPOSITION |
| JP2004115440A (en) * | 2002-09-26 | 2004-04-15 | Pola Chem Ind Inc | Calorigenic sympathetic nerve activator and composition containing the same |
| WO2004045604A1 (en) * | 2002-11-18 | 2004-06-03 | General Nutrition Investment Company | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| WO2004047765A3 (en) * | 2002-11-22 | 2004-10-21 | Shaklee Corp | Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass |
| JP2004292404A (en) * | 2003-03-28 | 2004-10-21 | Kanebo Ltd | Carbohydrate absorption inhibitor and food |
| JP2005289950A (en) * | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Lipase inhibitor comprising water extraction component of eucommia ulmoides leaf |
| JP2005289951A (en) * | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Lipase inhibitor comprising component of eucommia ulmoides leaf |
| EP1495764A4 (en) * | 2002-04-15 | 2005-11-16 | Tetsuo Santo | Drinking tea for treating dermatitis |
| JP2005350453A (en) * | 2004-05-14 | 2005-12-22 | Toyo Shinyaku:Kk | Slightly water-soluble component of leaf of lagerstroemia speciosa l. |
| JP2006016367A (en) * | 2004-07-05 | 2006-01-19 | Suntory Ltd | Lipase inhibitor |
| WO2006030567A1 (en) * | 2004-09-13 | 2006-03-23 | Chuon Co., Ltd. | Carbohydrase inhibitors derived from fagaceous plants and use thereof |
| EP1534082A4 (en) * | 2002-08-14 | 2006-05-10 | Bionutrigen Co Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| WO2006070618A1 (en) * | 2004-12-28 | 2006-07-06 | Asahi Breweries, Ltd. | Catecholamine regulator and foods, drinks, food additives and drugs containing the same |
| EP1759596A1 (en) * | 2004-04-21 | 2007-03-07 | Use-Techno Corporation | Process for producing whitish banaba extract, whitish banaba extract and food or drink containing whitish banaba extract |
| US7195783B2 (en) * | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| JP2007117005A (en) * | 2005-10-28 | 2007-05-17 | Nippon Clinic Kk | Diet food |
| WO2007119789A1 (en) * | 2006-04-13 | 2007-10-25 | Uha Mikakuto Co., Ltd. | Agent for suppressing arteriosclerosis |
| JP2007314475A (en) * | 2006-05-26 | 2007-12-06 | Kao Corp | Agent for suppressing triacylglycerol synthesis |
| JP2008044872A (en) * | 2006-08-11 | 2008-02-28 | Nippon Supplement Kk | Health food containing isolariciresinol, blood cholesterol-reducing agent and body fat-reducing agent |
| JP2008508284A (en) * | 2004-07-29 | 2008-03-21 | ミシガン ステイト ユニバーシティー | Methods and compositions for treating obesity, insulin related diseases, and hypercholesterolemia |
| US7476406B1 (en) * | 2004-05-17 | 2009-01-13 | Nse Products, Inc. | Multifaceted weight control system |
| US7744930B2 (en) | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| JP2010273569A (en) * | 2009-05-26 | 2010-12-09 | Wasaburo Sato | Drink and supplement each having metabolic syndrome-improving action |
| JP2011105763A (en) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar-dependent gene transcription activator |
| JP2011231078A (en) * | 2010-04-30 | 2011-11-17 | Nagaoka Koryo Kk | Oral intake composition effective for preventing and/or treating non-alcoholic fatty liver disease |
| JP2014118364A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
| WO2015033898A1 (en) * | 2013-09-03 | 2015-03-12 | サンスター株式会社 | Composition for improving blood sugar metabolism |
| KR20150084405A (en) | 2014-01-14 | 2015-07-22 | 목포대학교산학협력단 | Composition for Prevention and Treatment of Cardiovascular Diseases |
| JP2016500070A (en) * | 2012-11-21 | 2016-01-07 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | Composition for inhibiting amylase activity containing chitooligosaccharide |
| JP2016006021A (en) * | 2014-06-20 | 2016-01-14 | 株式会社ノエビア | Thioredoxin-related factor expression promoter |
| CN107080811A (en) * | 2017-05-09 | 2017-08-22 | 武汉钧安制药有限公司 | Treat Chinese medicine preparation of whelk and preparation method thereof |
| JP2018509430A (en) * | 2015-03-23 | 2018-04-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． | Drug composition containing silybin and L-carnitine |
| JP2018095595A (en) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | Fat accumulation inhibitor and food and drink containing same |
| JP2021017428A (en) * | 2019-07-23 | 2021-02-15 | 株式会社ファイン | α-AMYLASE ACTIVITY INHIBITORS AND METHODS FOR PRODUCING SAME |
| US10953067B2 (en) * | 2014-02-05 | 2021-03-23 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
-
1996
- 1996-02-20 JP JP8055402A patent/JPH09227398A/en active Pending
Cited By (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034630A1 (en) * | 1997-02-05 | 1998-08-13 | F.Hoffmann-La Roche Ag | Use of gastrointestinal lipase inhibitors |
| JPH10304848A (en) * | 1997-05-07 | 1998-11-17 | Hitachi Zosen Corp | Food having anti-hyperlipemic function |
| JPH11276148A (en) * | 1998-03-30 | 1999-10-12 | Kazuichi Watabe | Production of wine of hypericum erectum |
| JPH11332561A (en) * | 1998-05-22 | 1999-12-07 | Matsuura Yakugyo Kk | Angiotensin converting enzyme inhibitor |
| JP2000044484A (en) * | 1998-07-31 | 2000-02-15 | Higashimaru Shoyu Co Ltd | Amylase inhibition-active substance and its use |
| JP2000053568A (en) * | 1998-08-06 | 2000-02-22 | Taiyo Kagaku Co Ltd | Anti-obesity composition |
| JP2000191487A (en) * | 1998-12-29 | 2000-07-11 | Sunstar Inc | Oral cavity agent composition and food and drink composition for inhibiting matrix metalloprotease |
| WO2000054760A3 (en) * | 1999-03-15 | 2001-03-08 | Shaman Pharmaceuticals Inc | Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia |
| US7195783B2 (en) * | 1999-07-09 | 2007-03-27 | Fx Life Sciences International Gmbh | Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics |
| JP2001048802A (en) * | 1999-08-06 | 2001-02-20 | Kenko Tsusho Kk | Health auxiliary food effective for diabetes, method of using the same and food combination preparation effective for diabetes |
| JP2001103928A (en) * | 1999-10-08 | 2001-04-17 | Fancl Corp | Food composition |
| JP2001206893A (en) * | 1999-11-17 | 2001-07-31 | Sanpo Kk | NEW alpha-AMYLASE INHIBITORY ACTIVE SUBSTANCE, METHOD FOR PRODUCING THE SAME AND ITS USE |
| JP2001333733A (en) * | 2000-05-29 | 2001-12-04 | Okinawa Shokuryo Kk | alpha-AMYLASE INHIBITOR |
| JP4524022B2 (en) * | 2000-05-29 | 2010-08-11 | 沖縄食糧株式会社 | α-Amylase inhibitor |
| JP2011105763A (en) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ppar-dependent gene transcription activator |
| EP1166790A1 (en) * | 2000-06-28 | 2002-01-02 | Ito En, Ltd. | Sugar decomposition inhibitor, digestive enzyme activity inhibitor, insulin secretion controller, and healthy food and beverage |
| JP2002012547A (en) * | 2000-06-28 | 2002-01-15 | Ito En Ltd | Saccharide decomposition-inhibiting agent, insulin secretion-inhibiting agent, and health beverage or food |
| JP2002275077A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipase inhibitor |
| JP2003113106A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Expression promoter of uncoupling protein and composition containing the same |
| JP2003128563A (en) * | 2001-10-25 | 2003-05-08 | Ichimaru Pharcos Co Ltd | Cosmetic composition, drink or food |
| JP2003252766A (en) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | Antiobesity and/or antidiabetic agent containing cyanidin 3-glucoside as active component |
| JP2004000164A (en) * | 2002-03-29 | 2004-01-08 | Morinaga Milk Ind Co Ltd | alpha-GLUCOSIDASE INHIBITOR AND COMPOSITION |
| US7615239B2 (en) | 2002-04-15 | 2009-11-10 | Tetsuo Santo | Tea for treating dermatitis comprising herbal extracts |
| EP1495764A4 (en) * | 2002-04-15 | 2005-11-16 | Tetsuo Santo | Drinking tea for treating dermatitis |
| JP2003342185A (en) * | 2002-05-25 | 2003-12-03 | Bhn Kk | Inhibitor of lipase activity |
| US7867525B2 (en) * | 2002-08-14 | 2011-01-11 | Bionutrigen Co., Ltd. | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| EP1534082A4 (en) * | 2002-08-14 | 2006-05-10 | Bionutrigen Co Ltd | Powder or extracts of plant leaves with anti-obesity effects and anti-obesity food comprising them |
| JP4637447B2 (en) * | 2002-09-26 | 2011-02-23 | ポーラ化成工業株式会社 | Heat-producing sympathetic nerve activator and composition containing the same |
| JP2004115440A (en) * | 2002-09-26 | 2004-04-15 | Pola Chem Ind Inc | Calorigenic sympathetic nerve activator and composition containing the same |
| WO2004045604A1 (en) * | 2002-11-18 | 2004-06-03 | General Nutrition Investment Company | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite |
| WO2004047765A3 (en) * | 2002-11-22 | 2004-10-21 | Shaklee Corp | Compositions, methods, and kits for weight loss and inhibiting the loss of lean body mass |
| US7744930B2 (en) | 2002-11-22 | 2010-06-29 | Shaklee Corporation | Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass |
| JP2004189663A (en) * | 2002-12-11 | 2004-07-08 | Ichimaru Pharcos Co Ltd | Maillard reaction inhibitor |
| JP2004292404A (en) * | 2003-03-28 | 2004-10-21 | Kanebo Ltd | Carbohydrate absorption inhibitor and food |
| WO2005099735A1 (en) * | 2004-03-31 | 2005-10-27 | Kobayashi Pharmaceutical Co., Ltd. | Lipase inhibitor containing component of leaf of hardy rubber tree |
| JP2005289950A (en) * | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Lipase inhibitor comprising water extraction component of eucommia ulmoides leaf |
| WO2005099734A1 (en) * | 2004-03-31 | 2005-10-27 | Kobayashi Pharmaceutical Co., Ltd. | Lipase inhibitor containing water extract from leaf of hardy rubber tree |
| JP2005289951A (en) * | 2004-03-31 | 2005-10-20 | Kobayashi Pharmaceut Co Ltd | Lipase inhibitor comprising component of eucommia ulmoides leaf |
| EP1759596A1 (en) * | 2004-04-21 | 2007-03-07 | Use-Techno Corporation | Process for producing whitish banaba extract, whitish banaba extract and food or drink containing whitish banaba extract |
| EP1759596A4 (en) * | 2004-04-21 | 2007-08-22 | Use Techno Corp | Process for producing whitish banaba extract, whitish banaba extract and food or drink containing whitish banaba extract |
| JP2005350453A (en) * | 2004-05-14 | 2005-12-22 | Toyo Shinyaku:Kk | Slightly water-soluble component of leaf of lagerstroemia speciosa l. |
| US7476406B1 (en) * | 2004-05-17 | 2009-01-13 | Nse Products, Inc. | Multifaceted weight control system |
| JP2006016367A (en) * | 2004-07-05 | 2006-01-19 | Suntory Ltd | Lipase inhibitor |
| JP2008508284A (en) * | 2004-07-29 | 2008-03-21 | ミシガン ステイト ユニバーシティー | Methods and compositions for treating obesity, insulin related diseases, and hypercholesterolemia |
| JP2006104181A (en) * | 2004-09-13 | 2006-04-20 | Takahiro Tsujita | Glucide-splitting enzyme-inhibiting material derived from fagaceae plant and application thereof |
| WO2006030567A1 (en) * | 2004-09-13 | 2006-03-23 | Chuon Co., Ltd. | Carbohydrase inhibitors derived from fagaceous plants and use thereof |
| WO2006070618A1 (en) * | 2004-12-28 | 2006-07-06 | Asahi Breweries, Ltd. | Catecholamine regulator and foods, drinks, food additives and drugs containing the same |
| JP2007117005A (en) * | 2005-10-28 | 2007-05-17 | Nippon Clinic Kk | Diet food |
| JPWO2007119789A1 (en) * | 2006-04-13 | 2009-08-27 | ユーハ味覚糖株式会社 | Arteriosclerosis inhibitor |
| WO2007119789A1 (en) * | 2006-04-13 | 2007-10-25 | Uha Mikakuto Co., Ltd. | Agent for suppressing arteriosclerosis |
| JP2007314475A (en) * | 2006-05-26 | 2007-12-06 | Kao Corp | Agent for suppressing triacylglycerol synthesis |
| JP2008044872A (en) * | 2006-08-11 | 2008-02-28 | Nippon Supplement Kk | Health food containing isolariciresinol, blood cholesterol-reducing agent and body fat-reducing agent |
| JP2010273569A (en) * | 2009-05-26 | 2010-12-09 | Wasaburo Sato | Drink and supplement each having metabolic syndrome-improving action |
| JP2011231078A (en) * | 2010-04-30 | 2011-11-17 | Nagaoka Koryo Kk | Oral intake composition effective for preventing and/or treating non-alcoholic fatty liver disease |
| JP2016500070A (en) * | 2012-11-21 | 2016-01-07 | 株式会社アモーレパシフィックＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ | Composition for inhibiting amylase activity containing chitooligosaccharide |
| JP2018138582A (en) * | 2012-11-21 | 2018-09-06 | アモーレパシフィック コーポレーション | Amylase-activity-inhibiting composition containing chito-oligosaccharide |
| JP2014118364A (en) * | 2012-12-13 | 2014-06-30 | Pola Chem Ind Inc | Advanced glycation end product decomposer |
| WO2015033898A1 (en) * | 2013-09-03 | 2015-03-12 | サンスター株式会社 | Composition for improving blood sugar metabolism |
| TWI627962B (en) * | 2013-09-03 | 2018-07-01 | 日星股份有限公司 | Composition for improving blood glucose metabolism |
| EP3042661A1 (en) * | 2013-09-03 | 2016-07-13 | Sunstar Inc. | Composition for improving blood sugar metabolism |
| JPWO2015033898A1 (en) * | 2013-09-03 | 2017-03-02 | サンスター株式会社 | Composition for improving blood glucose metabolism |
| EP3042661A4 (en) * | 2013-09-03 | 2017-05-17 | Sunstar Inc. | Composition for improving blood sugar metabolism |
| US9801917B2 (en) | 2013-09-03 | 2017-10-31 | Sunstar Inc. | Composition for improving blood sugar metabolism |
| KR20150084405A (en) | 2014-01-14 | 2015-07-22 | 목포대학교산학협력단 | Composition for Prevention and Treatment of Cardiovascular Diseases |
| US10953067B2 (en) * | 2014-02-05 | 2021-03-23 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
| US11903991B2 (en) | 2014-02-05 | 2024-02-20 | Laila Nutraceuticals | Synergistic dietary supplement compositions for the prevention, treatment or control of inflammatory disorders |
| JP2016006021A (en) * | 2014-06-20 | 2016-01-14 | 株式会社ノエビア | Thioredoxin-related factor expression promoter |
| JP2018509430A (en) * | 2015-03-23 | 2018-04-05 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． | Drug composition containing silybin and L-carnitine |
| JP2018095595A (en) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | Fat accumulation inhibitor and food and drink containing same |
| WO2018110042A1 (en) * | 2016-12-14 | 2018-06-21 | 日清食品ホールディングス株式会社 | Fat accumulation inhibitor and food/beverage containing same |
| CN107080811A (en) * | 2017-05-09 | 2017-08-22 | 武汉钧安制药有限公司 | Treat Chinese medicine preparation of whelk and preparation method thereof |
| JP2021017428A (en) * | 2019-07-23 | 2021-02-15 | 株式会社ファイン | α-AMYLASE ACTIVITY INHIBITORS AND METHODS FOR PRODUCING SAME |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09227398A (en) | Antiobese agent | |
| KR101746415B1 (en) | Black rice bran fermentation and Preparation method of thereof, a cosmetic composition containing black rice bran fermentation as an active ingredients | |
| JP4658348B2 (en) | Collagen production promoter, collagenase inhibitor, fibroblast proliferation agent, elastase inhibitor, estrogen-like agent, and skin cosmetics | |
| KR100864373B1 (en) | Cosmetics containing sphingoglycolipids and a process for its production | |
| CN108697685A (en) | Containing moracin, Phellinus copper G or the root bark of white mulberry, the prevention of muscle disease and treatment is used or muscular function improvement composition | |
| JP2018035146A (en) | Extract of suberized ipomoea batatas or suberized arctium lappa | |
| JP2002293736A (en) | Maillard reaction inhibitor and composition containing the same | |
| KR101711002B1 (en) | Manufacturing method for an extract of the leaf of panax ginseng, and the cosmetic composition including the extract | |
| KR102022263B1 (en) | A composition comprising the fermented extract of Cinnamomum verum J. Presl, Ulmus davidiana var. japonica da and Acanthopanax sessiliflorum Seeman for preventing and treating benign prostatic hyperplasia | |
| KR20160037612A (en) | Composition for improving skin moisturization comprising royal jelly | |
| KR20160034573A (en) | Composition for improving skin moisturization comprising royal jelly | |
| KR20160004568A (en) | manufacturing method for an extract of the leaf of panax ginseng, and the cosmetic composition including the extract | |
| JP3404235B2 (en) | Anti-obesity agent | |
| CN102099049B (en) | Natrual inhibitor of the enzymatic production of 3-deoxy-glucosone | |
| JP2011055837A (en) | Food and drink for beautification | |
| KR100550165B1 (en) | Manufacturing method of water-soluble propolis | |
| CN114271489B (en) | Anti-saccharification health-care food composition | |
| JP2005220100A (en) | Anti-ageing agent, platelet aggregation inhibitor, antioxidant, anti-allergic agent, skin cosmetic, and food and drink | |
| KR100441722B1 (en) | Preparations to promote hair growth and method for producing thereof | |
| JP3590908B2 (en) | Enzyme inhibitor having α-amylase inhibitor activity or tyrosinase inhibitor activity and method for producing the same | |
| KR102607663B1 (en) | Composition for treating or improving liver disease and liver dysfunction comprising zizania latifolia extract | |
| KR20200036412A (en) | The method of vitamin C-used fermentation of pig skin | |
| JPH09278667A (en) | Composition having ability to scavenge active oxygen | |
| KR102155837B1 (en) | Anti-stress compositon containing Rhodiola sacra extracts and preparation method thereof | |
| KR102286969B1 (en) | Composition for improving skin conditions comprising omega-7 derived from refined fish oil and red ginseng |